Page 244 - 2020_01-Haematologica-web

S. Matsuoka et al.
18. J Leukoc Biol. 2007;82(1):142-151.
8. Imanishi T, Hara H, Suzuki S, Suzuki N, Akira S, Saito T. Cutting edge: TLR2 direct- ly triggers Th1 effector functions. J Immunol. 2007;178(11):6715-6719.
9. Reynolds JM, Martinez GJ, Chung Y, Dong C. Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci U S A. 2012;109(32):13064- 13069.
10. Chang J, Burkett PR, Borges CM, Kuchroo VK, Turka LA, Chang CH. MyD88 is essen- tial to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc Natl Acad Sci U S A. 2013;110(6):2270-2275.
11. Zhang Y, Jones M, McCabe A, Winslow GM, Avram D, MacNamara KC. MyD88 signaling in CD4 T cells promotes IFN- gamma production and hematopoietic pro- genitor cell expansion in response to intra- cellular bacterial infection. J Immunol. 2013;190(9):4725-4735.
12. Schenten D, Nish SA, Yu S, et al. Signaling through the adaptor molecule MyD88 in CD4+ T cells is required to overcome sup- pression by regulatory T cells. Immunity. 2014;40(1):78-90.
13. O'Donnell H, Pham OH, Li LX, et al. Toll- like receptor and inflammasome signals converge to amplify the innate bactericidal capacity of T helper 1 cells. Immunity. 2014;40(2):213-224.
14. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412-415.
15. Koyama M, Kuns RD, Olver SD, et al. Recipient nonhematopoietic antigen-pre- senting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med. 2011;18(1):135-142.
16. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflamma- tory cytokines. Blood. 1997;90(8):3204- 3213.
17. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003;78(3):181-187.
18. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102(10):1882-1891.
19. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus- leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107(12):1581-1589.
20. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-indepen- dent toll-like receptor signaling pathway. Science. 2003;301(5633):640-643.
21. Uryu H, Hashimoto D, Kato K, et al. alpha- Mannan induces Th17-mediated pul- monary graft-versus-host disease in mice. Blood. 2015;125(19):3014-3023.
22. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumo- nia syndrome after bone marrow transplan- tation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
23. Teshima T, Hill GR, Pan L, et al. IL-11 sep- arates graft-versus-leukemia effects from graft-versus-host disease after bone mar-
row transplantation. J Clin Invest. 1999;104
(3):317-325.
24. Edinger M, Hoffmann P, Ermann J, et al.
CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone mar- row transplantation. Nat Med. 2003; 9(9):1144-1150.
25. Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172(10):6065-6073.
26. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A. 2004;101(9):3029-3034.
27. Caron G, Duluc D, Fremaux I, et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol. 2005;175(3):1551-1557.
28. Reynolds JM, Pappu BP, Peng J, et al. Toll- like receptor 2 signaling in CD4(+) T lym- phocytes promotes T helper 17 responses and regulates the pathogenesis of autoim- mune disease. Immunity. 2010;32(5):692- 702.
29. Quigley M, Martinez J, Huang X, Yang Y. A critical role for direct TLR2-MyD88 signal- ing in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood. 2009;113(10):2256-2264.
30. Mercier BC, Cottalorda A, Coupet CA, Marvel J, Bonnefoy-Berard N. TLR2 engagement on CD8 T cells enables gener- ation of functional memory cells in response to a suboptimal TCR signal. J Immunol. 2009;182(4):1860-1867.
31. Ben-Sasson SZ, Hogg A, Hu-Li J, et al. IL-1 enhances expansion, effector function, tis- sue localization, and memory response of antigen-specific CD8 T cells. J Exp Med. 2013;210(3):491-502.
32. Heimesaat MM, Nogai A, Bereswill S, et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus- host disease. Gut. 2010;59(8):1079-1087.
33. Lee WS, Kim JY, Won HJ, et al. Effect of upregulated TLR2 expression from G-CSF- mobilized donor grafts on acute graft-ver- sus-host disease. Int Immunopharmacol. 2015;29(2):488-493.
34. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus- host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med. 2001;194(10):1433-1440.
35. Okamoto I, Kohno K, Tanimoto T, et al. IL- 18 prevents the development of chronic graft-versus-host disease in mice. J Immunol. 2000;164(11):6067-6074.
36. Min CK, Maeda Y, Lowler K, et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell sub- sets after experimental allogeneic bone marrow transplantation. Blood. 2004; 104(10):3393-3399.
37. Matta BM, Reichenbach DK, Zhang X, et al. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood. 2016;128(3):427-439.
38. Yu Y, Wang D, Liu C, et al. Prevention of GVHD while sparing GVL by targeting Th1 and Th17 transcription factor T-bet and ROR{gamma}t in mice. Blood. 2011;118
(18):5011-5020.
39. Lim JY, Ryu DB, Lee SE, Park G, Choi EY,
Min CK. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus- Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation. Mol Cells. 2015;38(11):966-974.
40. Zhang J, Ramadan AM, Griesenauer B, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2- expressing T cells during graft-versus-host disease. Sci Transl Med. 2015; 7(308):308ra160.
41. Jankovic D, Ganesan J, Bscheider M, et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med. 2013; 210(10):1899-1910.
42. Park MJ, Lee SH, Lee SH, et al. IL-1 Receptor Blockade Alleviates Graft-versus- Host Disease through Downregulation of an Interleukin-1beta-Dependent Glycolytic Pathway in Th17 Cells. Mediators Inflamm. 2015;2015:631384.
43. Antin JH, Weisdorf D, Neuberg D, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-con- trolled trial of interleukin-1 receptor antag- onist in allogeneic bone marrow transplan- tation. Blood. 2002;100(10):3479-3482.
44. Hultmark D. Macrophage differentiation marker MyD88 is a member of the Toll/IL- 1 receptor family. Biochem Biophys Res Commun. 1994;199(1):144-146.
45. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science. 1997;278(5343):1612-1615.
46. Suzuki N, Suzuki S, Millar DG, et al. A crit- ical role for the innate immune signaling molecule IRAK-4 in T cell activation. Science. 2006;311(5769):1927-1932.
47. Li H, Matte-Martone C, Tan HS, et al. Graft-versus-host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells. J Immunol. 2011;186(1):230-241.
48. Wu YW, Tang W, Zuo JP. Toll-like recep- tors: potential targets for lupus treatment. Acta Pharmacol Sin. 2015;36(12):1395- 1407.
49. Lee KL, Ambler CM, Anderson DR, et al. Discovery of Clinical Candidate 1- {[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrro- lidin-2-yl]methoxy}-7-methoxyisoquinoli ne-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017;60(13):5521-5542.
50. Kelly PN, Romero DL, Yang Y, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malig- nancy. J Exp Med. 2015;212(13):2189-2201.
51. Teshima T, Reddy P, Zeiser R. Acute Graft- versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant. 2016;22(1):11-16.
52. Zeiser R, Blazar BR. Acute Graft-versus- Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017; 377(22):2167-2179.
53. McDonald DR, Goldman F, Gomez-Duarte OD, et al. Impaired T-cell receptor activa- tion in IL-1 receptor-associated kinase-4- deficient patients. J Allergy Clin Immunol. 2010;126(2):332-337.
234
haematologica | 2020; 105(1)